Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | IL1RN | P18510 | 1/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16984879 | 1.00 | CTSB (0.55) | CTSBCAPN1MMEANPEPPOLB | |
| SCHEMBL21244283 | 1.00 | CTSB (0.55) | CTSBCAPN1MMEANPEPPOLB | |
| SCHEMBL27824395 | 0.92 | CTSK (0.58) | CTSBCTSK | |
| SCHEMBL11209394 | 0.92 | CTSK (0.58) | CTSBCTSK | |
| SCHEMBL11680813 | 0.90 | LTA4H (0.57) | CTSBCAPN1MMECTSK | |
| SCHEMBL20881521 | 0.90 | LTA4H (0.57) | CTSBCAPN1MMECTSK | |
| SCHEMBL22475577 | 0.90 | LTA4H (0.57) | CTSBCAPN1MMECTSK | |
| SCHEMBL11683261 | 0.90 | LTA4H (0.57) | CTSBCAPN1MMECTSK | |
| SCHEMBL11682299 | 0.90 | LTA4H (0.57) | CTSBCAPN1MMECTSK | |
| SCHEMBL7401701 | 0.90 | ALDH1A1 (0.53) | MMEALDH1A1THRBCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297678-B1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LTD (IN) | 2021-07-07 | — | — | EP | disclosed |
| US-10689416-B2 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190248837-A1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. | 2019-08-15 | — | — | US | disclosed |
| WO-2016185450-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248837-A1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | PSMB1, PSMB7, PSMB5 | CTSB 1480/4885CAPN1 1207/4885MME 567/4885 |
| US-10689416-B2 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | PSMB1, PSMB7, PSMB5 | CTSB 1480/4885CAPN1 1207/4885MME 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.